Biopsy-Free:
A Better Way

Access new treatment options with a breakthrough blood test.

In the eyes of a patient, the word biopsy encapsulates pain, agony and potential long recovery. Guardant360® is the gold standard in comprehensive liquid biopsy today.

Why Guardant360®?

Avoid the pain, complications and delays of invasive biopsies.


Biopsy‐free cancer treatment
First and only comprehensive non-invasive test for tumour sequencing and currently in clinical use.

Comprehensive
73-gene panel targets actionable somatic alterations.

Widely adopted
More than 3,000 oncologists.

Proven
Validation data in more than 15,000 patients.

Transforming cancer treatment
Timely results to help doctors make treatment decisions.

Who is the test for?

For patients:

  1. Where a tumor biopsy is not an option.
  2. Who have failed treatment.
  3. Who have metastatic cancer.

For patients with cancer type:

  • CUP
  • Bladder
  • Ovarian
  • NSCLC
  • Cholangio
  • Prostate
  • Lung Adeno
  • Colorectal
  • Pancreatic
  • Gastric
  • Breast
  • Melanoma
  • Glioblastoma

How long does it take to get the results?

How it works


Guardant360 starts with a simple blood draw.

We deeply sequence your cancer’s DNA using proprietary technology.

We deliver the genomic profile of your cancer. You and your doctor evaluate treatment options.

More information for clinicians

Specifications

Number of genes 73 genes.
Technology Proprietary digital sequencing technology identify the signal of patient’s individual genomic alterations from the noise of interfering data that is inherent to standard next-generation sequencing (NGS) techniques. Identify alterations across point mutations, amplification, fusions, and indels, including every guideline-recommended somatic alteration. This method gives Guardant360 single-molecule analytical sensitivity, 99.999% specificity, highest of any NGS method.
Performance Digital sequencing achieves near-perfect specificity.
Tumour advisory
board
Yes.
Types of Therapy Reported Guardant360 covers all somatic guideline-recommended genomic biomarkers for advanced solid tumors.
Validation Sample
Size
Validation data in more than 15,000 patients.

Complete sequencing of covered exons*

Point Mutations (SNVs)
73 Genes
Indels
23 Genes
Amplifications
18 Genes
Fusions
6 Genes
  • AKT1
  • ALK
  • APC
  • AR
  • ARAF
  • ARID1A
  • ATM
  • BRAF
  • BRCA1
  • BRCA2
  • CCND1
  • CCND2
  • CCNE1
  • CDH1
  • CDK4
  • CDK6
  • CDKN2A
  • CTNNB1
  • DDR2
  • EGFR
  • ERBB2 (HER2)
  • ESR1
  • EZH2
  • FBXW7
  • FGFR1
  • FGFR2
  • FGFR3
  • GATA3
  • GNA11
  • GNAQ
  • GNAS
  • HNF1A
  • HRAS
  • IDH1
  • IDH2
  • JAK2
  • JAK3
  • KIT
  • KRAS
  • MAP2K1/MEK1
  • MAP2K2/MEK2
  • MAPK1/ERK2
  • MAPK3/ERK1
  • MET
  • MLH1
  • MPL
  • MTOR
  • MYC
  • NF1
  • NFE2L2
  • NOTCH1
  • NPM1
  • NRAS
  • NTRK1
  • NTRK3
  • PDGFRA
  • PIK3CA
  • PTEN
  • PTPN11
  • RAF1
  • RB1
  • RET
  • RHEB
  • RHOA
  • RIT1
  • ROS1
  • SMAD4
  • SMO
  • STK11
  • TERT**
  • TP53
  • TSC1
  • VHL
  • ATM
  • APC
  • ARID1A
  • BRCA1
  • BRCA2
  • CDH1
  • CDKN2A
  • EGFR
  • ERBB2
  • GATA3
  • KIT
  • MET
  • MLH1
  • MTOR
  • NF1
  • PDGFRA
  • PTEN
  • RB1
  • SMAD4
  • STK11
  • TP53
  • TSC1
  • VHL
  • AR
  • BRAF
  • CCND1
  • CCND2
  • CCNE1
  • CDK4
  • CDK6
  • EGFR
  • ERBB2
  • FGFR1
  • FGFR2
  • KIT
  • KRAS
  • MET
  • MYC
  • PDGFRA
  • PIK3CA
  • RAF1
  • ALK
  • FGFR2
  • FGFR3
  • NTRK1
  • RET
  • ROS1

* Exons selected to maximize detection of known somatic mutations. List available upon request.
** Includes TERT promoter region.